This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nabilone & Marijuana Addiction

This study has been completed.
Information provided by:
University of British Columbia Identifier:
First received: December 2, 2009
Last updated: February 16, 2011
Last verified: February 2011
Safety of Nabilone in reducing marijuana craving

Condition Intervention Phase
Marijuana Smoking Drug: Cesemat Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Resource links provided by NLM:

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Safety and tolerability to Nabilone

Secondary Outcome Measures:
  • Marijuana craving questionnaire

Estimated Enrollment: 35
Study Start Date: June 2009
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cesemat Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone
No Intervention: Placebo

Detailed Description:
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01025700

Canada, British Columbia
Vancouver General Hospital - Psychiatry Outpatient
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Principal Investigator: Shaohua Lu, MD University of British Columbia
  More Information

Responsible Party: Shaohua Lu, MD, University of British Columbia Identifier: NCT01025700     History of Changes
Other Study ID Numbers: H08-01999
Study First Received: December 2, 2009
Last Updated: February 16, 2011

Keywords provided by University of British Columbia:

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on September 21, 2017